На этой странице перечислены больницы направления «Кардиология» (включая Hypertension Treatment) в Мумбаи, Индия, включая Nanavati Super Specialty Hospital, Kokilaben Dhirubhai Ambani Hospital, Tata Memorial Hospital, Apollo Hospitals, Navi Mumbai и другие.
Спросите нас о «Hypertension Treatment» в Мумбаи, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 17 аккредитованных больниц (Кардиология) в Мумбаи, Индия
Рекомендуем🇮🇳 Nanavati Super Specialty Hospital
Больница занимает 1-е место в этом списке по указанному рейтингу (5/5, 12 отзывов).
🇮🇳 Kokilaben Dhirubhai Ambani Hospital
Больница занимает 2-е место в этом списке по указанному рейтингу (4.8/5, 1800 отзывов).
🇮🇳 Tata Memorial Hospital
Больница занимает 3-е место в этом списке по указанному рейтингу (4.8/5, 2500 отзывов).
🇮🇳 Apollo Hospitals, Navi Mumbai
Больница занимает 4-е место в этом списке по указанному рейтингу (4.8/5, 512 отзывов).
🇮🇳 Gleneagles Hospital, Mumbai
Больница занимает 5-е место в этом списке по указанному рейтингу (4.8/5, 615 отзывов).
🇮🇳 Lilavati Hospital And Research Centre
Больница занимает 6-е место в этом списке по указанному рейтингу (4.8/5, 724 отзывов).
🇮🇳 Jaslok Hospital
Больница занимает 7-е место в этом списке по указанному рейтингу (4.6/5, 129 отзывов).
🇮🇳 Gleneagles Global Hospitals (Global Hospitals)
Больница занимает 8-е место в этом списке по указанному рейтингу (4.6/5, 183 отзывов).
🇮🇳 Medicover Hospital, Navi Mumbai
Больница занимает 9-е место в этом списке по указанному рейтингу (4.6/5, 143 отзывов).
🇮🇳 KIMS Hospitals, Thane
Больница занимает 10-е место в этом списке по указанному рейтингу (4.6/5, 58 отзывов).
🇮🇳 Fortis Hospital, Mulund
Больница занимает 11-е место в этом списке по указанному рейтингу (4.5/5, 79 отзывов).
🇮🇳 Fortis Hiranandani Hospital, Vashi
Больница занимает 12-е место в этом списке по указанному рейтингу (4.5/5, 83 отзывов).
🇮🇳 Wockhardt Hospital
Больница занимает 13-е место в этом списке по указанному рейтингу (4.4/5, 30 отзывов).
🇮🇳 Wockhardt Super Speciality Hospital
Больница занимает 14-е место в этом списке по указанному рейтингу (4.4/5, 48 отзывов).
🇮🇳 S. L. Raheja Hospital
Больница занимает 15-е место в этом списке по указанному рейтингу (4.4/5, 121 отзывов).
🇮🇳 Saifee Hospital
Больница занимает 16-е место в этом списке по указанному рейтингу (4.3/5, 97 отзывов).
🇮🇳 Dr. L H Hiranandani Hospital
Больница занимает 17-е место в этом списке по указанному рейтингу (4.3/5, 141 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Кардиология» указано среди её специализаций и она находится в Мумбаи, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «hypertension treatment» в Мумбаи, Индия?
Выбор подходящей больницы для «hypertension treatment» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Кардиология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Hypertension Treatment»
Hypertension, or persistently elevated blood pressure, is a chronic cardiovascular condition requiring precise, evidence-based management to prevent end-organ damage to the heart, kidneys, brain, and vasculature. With success rates exceeding 90% for achieving target blood pressure control through individualized pharmacotherapy and interventional strategies, patients from across the globe travel to India and the UAE to access world-class cardiologists, renal physicians, and advanced diagnostic infrastructure at a fraction of Western costs. GAF Healthcare connects international patients with JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed centers in Dubai and Abu Dhabi, providing seamless end-to-end care coordination for hypertension evaluation, treatment, and long-term management. Hospital Stay: 2–5 days (for intensive evaluation, crisis management, or interventional procedures such as renal denervation; outpatient programs require no overnight stay) • Total Stay in Country (Fit-to-Fly): 1–3 weeks (depending on whether treatment is medical optimization, procedural intervention, or hypertensive emergency management; blood pressure must be stable and below 160/100 mmHg before long-haul flight clearance) • Success Rate: 90–95% (achieving guideline-defined target blood pressure control: <130/80 mmHg for most patients, per ESC/AHA 2023 guidelines)
Clinical Overview
Hypertension is defined as a sustained systolic blood pressure ≥130 mmHg and/or diastolic ≥80 mmHg (AHA/ACC 2017 guidelines) or ≥140/90 mmHg (ESC 2018 guidelines), and it represents the single largest modifiable risk factor for stroke, myocardial infarction, heart failure, chronic kidney disease, and peripheral arterial disease. The underlying pathophysiology involves dysregulation of the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system hyperactivation, endothelial dysfunction, arterial stiffness, and sodium-volume dysregulation. In approximately 90–95% of cases, hypertension is classified as primary (essential), with no single identifiable cause; in 5–10% it is secondary, driven by identifiable etiologies including primary aldosteronism, renal artery stenosis, obstructive sleep apnea, pheochromocytoma, or Cushing's syndrome — all of which are systematically screened for at GAF Healthcare partner centers. The physiological cascade of uncontrolled hypertension inflicts progressive target-organ damage: left ventricular hypertrophy leading to diastolic dysfunction and eventual heart failure with preserved ejection fraction (HFpEF), hypertensive nephrosclerosis progressing to CKD, lacunar infarcts and white matter changes in the brain, and accelerated atherosclerosis in coronary and peripheral arteries. Risk stratification tools such as the Framingham Risk Score, the ESC SCORE2, and the ASCVD 10-year risk calculator are routinely applied to determine the urgency and intensity of blood pressure reduction and the need for concomitant cardiovascular risk factor modification including statin therapy and antiplatelet agents. The modern standard of care for hypertension integrates ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring (HBPM) to eliminate white-coat and masked hypertension artifacts, advanced echocardiography to assess left ventricular mass index (LVMI) and diastolic parameters, renal Doppler ultrasound, and where indicated, adrenal CT or venous sampling. Pharmacological management follows a stepped-care algorithm anchored on four cornerstone drug classes: Angiotensin-Converting Enzyme Inhibitors (ACEi) or Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers (CCBs), and thiazide-type or thiazide-like diuretics. For resistant hypertension, newer agents including finerenone (a non-steroidal mineralocorticoid receptor antagonist), aprocitentan (dual endothelin receptor antagonist), and device-based therapies such as catheter-based renal denervation and baroreflex activation therapy (BAT) represent the cutting edge of management — all available at select GAF Healthcare partner institutions.
Who is a Candidate?
• Patients with newly diagnosed or poorly controlled hypertension (BP consistently >140/90 mmHg on two or more readings) seeking comprehensive evaluation and optimized medical therapy • Individuals with suspected secondary hypertension (young patients, resistant to ≥3 medications, with clinical clues such as hypokalemia, adrenal incidentaloma, or renal bruit) requiring specialized investigation including aldosterone-to-renin ratio, renal artery Doppler, 24-hour urinary catecholamines/metanephrines, or overnight dexamethasone suppression test • Patients with resistant hypertension (blood pressure uncontrolled despite ≥3 antihypertensive agents including a diuretic at optimal doses, with adherence confirmed) who are candidates for renal denervation or baroreflex activation therapy • Individuals with hypertensive urgency or emergency (BP >180/120 mmHg with or without acute end-organ damage) requiring inpatient parenteral management and monitoring • Patients with hypertension-associated target organ damage: left ventricular hypertrophy (LVMI >115 g/m² in men, >95 g/m² in women), microalbuminuria (UACR 30–300 mg/g), eGFR <60 mL/min/1.73m², or subclinical atherosclerosis on carotid intima-media thickness (CIMT) assessment • Required diagnostics prior to treatment initiation: 24-hour Ambulatory Blood Pressure Monitoring (ABPM), fasting lipid panel, HbA1c, serum electrolytes (Na, K, Mg), serum creatinine and eGFR, urine albumin-to-creatinine ratio (UACR), 12-lead ECG, transthoracic echocardiogram (ECHO) for LV mass and function, renal ultrasound with Doppler, and fundoscopy for hypertensive retinopathy grading (Keith-Wagener-Barker classification) • Contraindications / Special Caution: bilateral renal artery stenosis (contraindication to ACEi/ARBs and renal denervation), pregnancy (requires specialized antihypertensive regimens — labetalol, nifedipine, methyldopa), severe aortic stenosis, eGFR <15 mL/min/1.73m² (limits drug class selection), known allergy to contrast agents (requires premedication for angiographic procedures), and patients with white-coat hypertension confirmed by ABPM (pharmacotherapy not indicated)
Treatment Options & Approaches
LIFESTYLE AND NON-PHARMACOLOGICAL INTERVENTIONS (First-Line for Stage 1 Hypertension, Adjunct for All Stages): Structured therapeutic lifestyle modification remains the foundation of hypertension management. GAF Healthcare partner centers offer medically supervised programs including the DASH (Dietary Approaches to Stop Hypertension) dietary protocol (targeting sodium intake <2.3 g/day and increased potassium to 3.5–5 g/day), aerobic exercise prescription (150 minutes/week of moderate-intensity activity reduces systolic BP by 5–8 mmHg), weight reduction (1 mmHg systolic reduction per 1 kg lost), alcohol moderation (≤14 units/week men, ≤8 units/week women), and structured smoking cessation programs. These interventions are combined with continuous remote blood pressure monitoring platforms for real-time physician oversight. PHARMACOLOGICAL MANAGEMENT — STEPPED-CARE ALGORITHM: Step 1 (Monotherapy or Dual Combination): ACE inhibitors (ramipril, perindopril) or ARBs (telmisartan, olmesartan) are first-line for patients with diabetes, CKD, or high cardiovascular risk. CCBs (amlodipine, lercanidipine) are first-line for elderly patients and those with isolated systolic hypertension. Thiazide-like diuretics (indapamide) are preferred over thiazides (hydrochlorothiazide) for superior cardiovascular outcome data. Step 2 (Triple Combination — RAS blocker + CCB + Diuretic): The ACE/ARB + CCB + thiazide-like diuretic triple combination is the guideline-recommended regimen and achieves control in 70–80% of patients. Step 3 (Resistant Hypertension Addition): Low-dose spironolactone (25–50 mg/day) is the most effective fourth-line agent, reducing BP by 20–25/10 mmHg on average in confirmed resistant hypertension. Beta-blockers (bisoprolol, carvedilol) are added in patients with concurrent heart failure or atrial fibrillation. Newer agents include finerenone (non-steroidal MRA), aprocitentan (daridorexant class), and amiloride. INTERVENTIONAL / DEVICE-BASED THERAPIES FOR RESISTANT HYPERTENSION: • Catheter-Based Renal Denervation (RDN): A minimally invasive endovascular procedure performed under conscious sedation or light general anesthesia. Using a dedicated catheter system (Symplicity Spyral™ by Medtronic or Paradise™ Ultrasound RDN System by ReCor Medical), radiofrequency or ultrasound energy is delivered circumferentially to the renal artery adventitia to ablate afferent and efferent sympathetic renal nerve fibers. SPYRAL HTN-ON MED and RADIANCE II trials demonstrated sustained systolic BP reductions of 6–9 mmHg compared to sham at 3 months. Procedure time: 45–90 minutes. Hospital stay: 1–2 days. • Baroreflex Activation Therapy (BAT — Barostim Neo™): An implantable neurostimulation device placed subcutaneously below the clavicle, with a lead surgically attached to the carotid sinus. Electrical stimulation of carotid baroreceptors chronically reduces sympathetic outflow and increases parasympathetic tone, achieving sustained BP reductions of 12–24 mmHg systolic in the BeAT-HF and Rheos Pivotal Trial data. Indicated for resistant hypertension with concomitant HFrEF. • Renal Artery Stenting: For hypertension caused by hemodynamically significant renal artery stenosis (>70% stenosis with FFR-confirmed ischemia), percutaneous transluminal renal angioplasty (PTRA) with drug-eluting stent placement can cure or substantially improve blood pressure control in appropriately selected patients (fibromuscular dysplasia responds better than atherosclerotic stenosis). • Adrenal Surgery (Laparoscopic Adrenalectomy): The definitive cure for primary aldosteronism confirmed by adrenal vein sampling (AVS) showing lateralized aldosterone excess. Laparoscopic unilateral adrenalectomy achieves biochemical cure in >98% and clinical hypertension cure/improvement in 80–90% of patients. Performed using a 3–4 port laparoscopic retroperitoneal approach for reduced recovery time (hospital stay: 2–3 days). • Pheochromocytoma Resection: For catecholamine-secreting adrenal tumors, laparoscopic or robotic-assisted adrenalectomy is performed following 10–14 days of alpha-blockade (phenoxybenzamine or doxazosin) and volume repletion, followed by beta-blockade. Robotic platforms (da Vinci Xi) at GAF Healthcare partner centers enable precise dissection in challenging anatomical locations.
Восстановление
PHASE 1 — PRE-ARRIVAL PREPARATION (2–4 weeks before travel): Patients submit medical records, home blood pressure logs, current medication list, and prior investigation reports through GAF Healthcare's secure online portal. A dedicated case manager assigns a consultant cardiologist or nephrologist who reviews records and issues a preliminary treatment plan within 48 hours. Patients are advised to bring a minimum 4-week supply of current antihypertensive medications (with generic/INN names confirmed), and to continue current therapy without interruption to avoid rebound hypertension during travel. A pre-travel blood pressure target of <160/100 mmHg is required for fitness to fly on arrival. PHASE 2 — DAY 1 TO DAY 3 (Arrival and Comprehensive Evaluation): On Day 1, patients undergo hospital admission (if inpatient evaluation) or outpatient registration. A comprehensive baseline assessment is completed: 24-hour ABPM placement, fasting bloodwork (renal panel, electrolytes, lipids, HbA1c, aldosterone-renin ratio, plasma metanephrines), urinalysis with UACR, 12-lead ECG, and a detailed clinical examination including fundoscopy. Echocardiography (transthoracic, with tissue Doppler imaging for diastolic function and LV mass index quantification) is performed on Day 1 or 2. Renal Doppler ultrasound and, if indicated, CT adrenal with fine cuts or MRI adrenal are completed by Day 2. A multidisciplinary team (cardiologist, nephrologist, endocrinologist, dietitian) case conference occurs on Day 2–3 to formulate the definitive treatment plan. PHASE 3 — DAYS 3–7 (Treatment Initiation or Procedure): For medical management optimization: The treating physician adjusts, rationalizes, or initiates antihypertensive therapy based on investigation results, guided by individualized hemodynamic data from the ABPM. For spironolactone initiation, serum potassium and renal function are rechecked at 72 hours. Blood pressure response is assessed with daily readings. For renal denervation: The procedure is performed on Day 3–4 in the cardiac catheterization laboratory. Post-procedure observation occurs for 24 hours with continuous BP telemetry. Discharge on Day 5 with outpatient follow-up on Day 7. For laparoscopic adrenalectomy: Surgery is performed under general anesthesia (Day 4–5). Post-operative electrolytes and aldosterone levels are checked on Days 1 and 2 post-surgery. Oral intake resumes within 24 hours. Hospital discharge by Day 7–8. PHASE 4 — DAYS 7–21 (In-Country Recovery and Monitoring): All patients remain in the country for a minimum of 7–14 days post-procedure (or post-medication optimization initiation) for supervised blood pressure response assessment. Follow-up clinic visits are scheduled on Days 7, 10, and 14. Anti-hypertensive medications are titrated based on home readings and repeat clinic BP measurements. For post-surgical patients, wound check and staple/suture removal occur at Day 10. Before departure, a formal 'fit-to-fly' assessment is conducted: BP must be stable and below 160/100 mmHg, renal function stable (creatinine within 20% of baseline), potassium in the normal range (3.5–5.0 mEq/L), and no postural hypotension on standing. PHASE 5 — POST-RETURN FOLLOW-UP (Weeks 4–12): GAF Healthcare facilitates telemedicine follow-up consultations at 4 weeks, 8 weeks, and 12 weeks post-return. Patients upload home blood pressure logs and local laboratory results (renal function, electrolytes) for virtual review by the treating physician. Medication adjustments are communicated in writing through the patient portal with specific dosing instructions and safety monitoring guidance.
Возможные риски
Hypertension treatment, while generally safe, carries specific risks that patients and clinicians must carefully weigh. Pharmacological management risks include: hypotension and syncope (particularly with aggressive BP reduction in elderly patients or those with carotid artery disease — the J-curve phenomenon is clinically relevant in patients with diastolic BP <70 mmHg); ACEi-induced angioedema (occurs in 0.1–0.3% of patients; higher incidence in patients of African descent and with concurrent mTOR inhibitor use); hyperkalemia with RAAS blockers combined with aldosterone antagonists (risk elevated in CKD eGFR <45); ARB/ACEi-induced acute kidney injury in bilateral renal artery stenosis; thiazide-induced hyponatremia, hypokalemia, hyperuricemia, and new-onset diabetes mellitus; and beta-blocker masking of hypoglycemia symptoms in insulin-dependent diabetics. Renal denervation carries procedural risks including renal artery dissection or perforation (<1%), access-site hematoma, transient renal function decline, and the theoretical risk of renal artery stenosis at the ablation site (long-term data up to 36 months show no significant stenosis signal in SPYRAL ON-MED data). Laparoscopic adrenalectomy risks include intraoperative hypertensive crisis during tumor manipulation (mitigated by pre-operative alpha-blockade), hemorrhage, conversion to open surgery (2–5%), adjacent organ injury, and post-operative adrenal insufficiency if bilateral adrenalectomy is required. Over-treatment risks are clinically significant: excessive blood pressure lowering (SBP <120 mmHg) is associated with increased risk of acute kidney injury, falls, and in patients with established coronary artery disease, potential ischemic events due to impaired coronary perfusion pressure. All GAF Healthcare partner centers implement individualized BP targets — <130/80 mmHg for most patients but <140/90 mmHg for those ≥65 years with high fall risk or CKD Stage 3b+ — with regular safety monitoring of renal function and electrolytes throughout the treatment course.
Почему GAF Healthcare
GAF Healthcare provides comprehensive non-medical logistical support specifically tailored for international patients traveling to India or the UAE for hypertension treatment. INDIA LOGISTICS: GAF Healthcare assists patients in obtaining an e-Medical Visa (eMV), which is available to citizens of over 150 eligible countries through India's online e-Visa portal. The eMV permits a stay of up to 60 days (extendable) with triple entry, and is typically processed within 3–5 business days. Required documents — including a letter of medical necessity from a GAF Healthcare partner hospital — are prepared and submitted on the patient's behalf. Priority appointments at NABH- and JCI-accredited hospitals in Chennai, Mumbai, Delhi, Bengaluru, and Hyderabad are coordinated with confirmed dates before visa application. Airport-to-hospital transfers are provided in air-conditioned vehicles with a GAF Healthcare patient coordinator present. Dedicated medical interpreters fluent in Arabic, Russian, French, Swahili, and other languages are available for all consultations and procedures. Accommodation for one accompanying attendant is arranged in hospital guest houses or partner hotels within 500 meters of the treating facility, with rates pre-negotiated for GAF Healthcare patients (typically USD 30–80 per night in India). UAE LOGISTICS (DUBAI / ABU DHABI): Citizens of over 50 nationalities receive visa-free entry to the UAE for 30–90 days, including most GCC, EU, UK, US, and Commonwealth passport holders. Patients from other nationalities receive assistance with UAE tourist or medical visit visa applications through GAF Healthcare's UAE-based coordinators. JCI- and DHA-licensed hospitals in Dubai Healthcare City, Jumeirah, and Abu Dhabi are accessible with same-week appointment scheduling. Luxury patient concierge services are available, including private airport transfers, hotel-to-hospital transport, and accommodation arrangements ranging from serviced apartments to 5-star medical tourism packages. Multilingual patient liaisons fluent in Arabic, Hindi, Urdu, Russian, and English are embedded within partner hospitals. GAF Healthcare's UAE coordinators also assist with insurance pre-authorization for patients holding international health insurance plans accepted at DHA-licensed institutions. ACROSS BOTH DESTINATIONS: All patients receive a dedicated GAF Healthcare case manager as a single point of contact from inquiry through post-return follow-up. Telemedicine pre-consultation is arranged before travel to allow the treating physician to review all records, request any pre-travel investigations, and provide written pre-arrival instructions. Emergency contact numbers for 24/7 medical support are provided for the duration of the patient's stay.
Частые вопросы о процедуре «Hypertension Treatment»
What is the cost of Hypertension Treatment in India vs. the UAE?
How long do I need to stay in the country before I am fit to fly home after Hypertension Treatment?
What is the success rate of Hypertension Treatment?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «hypertension treatment» в Мумбаи, Индия
Найдите лучшие больницы для «hypertension treatment» в Мумбаи, Индия
На этой странице представлено 17 больниц в Мумбаи, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Hypertension Treatment» в Мумбаи, Индия
Сколько больниц направления «Кардиология» представлено в Мумбаи, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Мумбаи, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Hypertension Treatment» в Мумбаи, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.